Breast Cancer

Combined Therapies Increase Adverse Events in Patients With Hormone Receptor–Positive Metastatic Breast Cancer

In patients with hormone receptor–positive metastatic breast cancer, the combination of targeted agents and hormone therapy is associated with a significantly increased risk of severe...

Palliative Care

Concurrent Palliative Care: Recommendations From the ASCO Clinical Practice Guideline

Updated in 2016, the ASCO clinical practice guideline on the integration of palliative care into standard oncology care provides evidence-based recommendations to oncology clinicians...

Hematologic Malignancies

Obinutuzumab-Based First-Line Treatment Improves Progression-Free Survival vs Rituximab-Based Treatment in Follicular Lymphoma

In the phase III GALLIUM trial reported in The New England Journal of Medicine by Robert Marcus, MBBS, of University College London, and colleagues, obinutuzumab (Gazyva)-based...


More Top Stories


William G. Wierda, MD, PhD, on CLL: How to Sequence Therapy

Louis M. Weiner, MD, Appointed Director of MedStar Georgetown Cancer Institute

MedStar Health, the largest not-for-profit health-care system across Maryland and the Washington, DC, region, has named Louis M. Weiner, MD, as Director of its MedStar Georgetown Cancer Institute. Dr. Weiner will serve in this capacity while also remaining Director of Georgetown Lombardi...


Anti–PD-L1 Antibody in Advanced Urothelial Carcinoma After Platinum Failure

As reported in The Lancet Oncology by Patel et al, the anti–programmed cell death ligand 1 (PD-L1) antibody avelumab (Bavencio) produced durable responses in patients with locally advanced or metastatic urothelial carcinoma after failure of platinum-based therapy in two expansion cohorts of...

Breast Cancer

Harold J. Burstein, MD, PhD, on HR+ Early Breast Cancer: Update of the SOFT Trial

Honor a Loved One With a Gift to Conquer Cancer

This holiday season, fund breakthrough cancer research on behalf of someone you love.  Visit CONQUER.ORG/Tribute-Gift to make a tax-deductible gift to Conquer Cancer, ASCO’s affiliate, and send an eCard or mailed notification of your donation. Your support will help fuel the brightest...

Mount Sinai Institutes Join $215 Million Partnership to Increase Patients’ Immunotherapy Success

The Tisch Cancer Institute and the Precision Immunology Institute at Mount Sinai Health System are part of a $215 million public-private Cancer Moonshot research collaboration launched by the National Institutes of Health and 11 leading pharmaceutical companies. The 5-year initiative, called...

Primary Tumor Location and Outcomes in Stage III Colon Cancer According to RAS- and BRAF-Mutation Status

  In a study in the PETACC-8 trial population reported in JAMA Oncology, Taieb et al found that the risk of recurrence in patients with stage III colon cancer differed for the primary tumor location according to RAS- and BRAF-mutation status. Study Details A total of 2,559 patients were...

Palliative Care

Areej El-Jawahri, MD, on A Revolutionary Plan for End-of-Life Care

Hematologic Malignancies
Multiple Myeloma

CAR T-Cell Therapy Makes Further Inroads in Lymphoma and Myeloma

With the recent U.S. Food and Drug Administration (FDA) approvals of two chimeric antigen receptor (CAR) T-cell products, this novel approach seems to be moving into the mainstream. The approvals were tisagenlecleucel (also known as CTL019; Kymriah) for the treatment of pediatric B-cell acute...


ASH 2017: Low–Molecular-Weight Heparin/Edoxaban vs Dalteparin for VTE Associated With Cancer

People with cancer face an increased risk for venous thromboembolism (VTE). Under current guidelines, cancer patients who develop VTE are prescribed low–molecular-weight heparin, an anticoagulant that must be injected under the skin daily for several months. While effective, this regimen can...